Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 20/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19116644 | 0.94 | EPHX2 (0.89) | EPHX2 | |
| SCHEMBL1060536 | 0.94 | EPHX2 (1.00) | EPHX2 | |
| SCHEMBL19116378 | 0.93 | EPHX2 (0.87) | EPHX2 | |
| SCHEMBL1065643 | 0.93 | EPHX2 (1.00) | EPHX2 | |
| SCHEMBL1061376 | 0.89 | EPHX2 (1.00) | EPHX2 | |
| SCHEMBL1066006 | 0.89 | EPHX2 (1.00) | EPHX2 | |
| SCHEMBL12931923 | 0.89 | EPHX2 (1.00) | EPHX2 | |
| SCHEMBL1065057 | 0.89 | EPHX2 (1.00) | EPHX2 | |
| SCHEMBL4009860 | 0.89 | EPHX2 (1.00) | EPHX2 | |
| SCHEMBL13651431 | 0.89 | EPHX2 (1.00) | EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 177 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230071934-A1 | NOVEL USES | INTRA-CELLULAR THERAPIES, INC. | 2023-03-09 | — | — | US | claimed |
| WO-2021127517-A1 | NOVEL USES | INTRA-CELLULAR THERAPIES, INC. (US) | 2021-06-24 | — | — | WO | claimed |
| US-20160256457-A1 | METHODS FOR TREATING OR PREVENTING ACUTE VASCULAR LEAK | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2016-09-08 | — | — | US | claimed |
| EP-1904050-B1 | USE OF CIS-EPOXYEICOSATRIENOIC ACIDS AND INHIBITORS OF SOLUBLE EPOXIDE HYDROLASE TO REDUCE CARDIOMYOPATHY | UNIV CALIFORNIA (US) | 2012-11-14 | — | — | EP | claimed |
| US-8242170-B2 | Use of cis-epoxyeicosatrienoic acids and inhibitors of soluble epoxide hydrolase to reduce cardiomyopathy | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2012-08-14 | — | — | US | claimed |
| US-20090216318-A1 | Use of cis-epoxyeicosatrienoic acids and inhibitors of soluble epoxide hydrolase to reduce cardiomyopathy | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2009-08-27 | — | — | US | claimed |
| EP-1765311-A4 | REDUCING NEPHROPATHY WITH INHIBITORS OF SOLUBLE EPOXIDE HYDROLASE AND EPOXYEICOSANOIDS | UNIV CALIFORNIA (US) | 2009-04-29 | — | — | EP | claimed |
| US-20090018092-A1 | Reducing Nephropathy with Inhibitors of Soluble Epoxide Hydrolase and Epoxyeicosanoids | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2009-01-15 | — | — | US | claimed |
| EP-1765311-A2 | REDUCING NEPHROPATHY WITH INHIBITORS OF SOLUBLE EPOXIDE HYDROLASE AND EPOXYEICOSANOIDS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2007-03-28 | — | — | EP | claimed |
| EP-1737443-A2 | USE OF CIS-EPOXYEICOSANTRIENOIC ACIDS AND INHIBITORS OF SOLUBLE EPOXIDE HYDROLASE TO REDUCE PULMONARY INFILTRATION BY NEUTROPHILS | The Regents of the University of California (US) | 2007-01-03 | — | — | EP | claimed |
| WO-2005094373-A2 | CIS-EPOXYEICOSANTRIENOIC ACIDS AND INHIBITORS OF SOLUBLE EPOXIDE HYDROLASE AND METHODS TO REDUCE PULMONARY INFILTRATION BY NEUTROPHILS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2005-10-13 | — | — | WO | claimed |
| WO-2005089380-A2 | REDUCING NEPHROPATHY WITH INHIBITORS OF SOLUBLE EPOXIDE HYDROLASE AND EPOXYEICOSANOIDS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2005-09-29 | — | — | WO | claimed |
| US-20260130877-A1 | TREATMENT OF NEURODEVELOPMENTAL DISORDERS | THE REGENTS OF THE UNIV OF CALIFORNIA (US) | 2026-05-14 | — | — | US | disclosed |
| US-12357598-B2 | Treatment of neurodevelopmental disorders | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2025-07-15 | — | — | US | disclosed |
| US-12251379-B2 | Methods of inhibiting formation of alpha synuclein aggregates | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2025-03-18 | — | — | US | disclosed |
| US-20230301949-A1 | TREATMENT OF NEURODEVELOPMENTAL DISORDERS | CHIBA UNIVERSITY (JP) | 2023-09-28 | — | — | US | disclosed |
| WO-2005089380-A2 | REDUCING NEPHROPATHY WITH INHIBITORS OF SOLUBLE EPOXIDE HYDROLASE AND EPOXYEICOSANOIDS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2005-09-29 | — | — | WO | disclosed |
| US-20050164951-A1 | Inhibitors for the soluble epoxide hydrolase | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2005-07-28 | — | — | US | disclosed |
| US-20050026844-A1 | Inhibitors for the soluble epoxide hydrolase | REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2005-02-03 | — | — | US | disclosed |
| WO-2004089296-A2 | IMPROVED INHIBITORS FOR THE SOLUBLE EPOXIDE HYDROLASE | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2004-10-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230301949-A1 | TREATMENT OF NEURODEVELOPMENTAL DISORDERS | FABP7, ADH1B, ELOVL1 | EPHX2 51/4885 |
| US-12357598-B2 | Treatment of neurodevelopmental disorders | FABP7, ADH1B, ELOVL1 | EPHX2 51/4885 |
| US-20050164951-A1 | Inhibitors for the soluble epoxide hydrolase | EPHX1, EPHX2, NCEH1 | EPHX2 2/4885 |
| US-20260130877-A1 | TREATMENT OF NEURODEVELOPMENTAL DISORDERS | EED, ICOS, FABP7 | EPHX2 10/4885 |
| US-12251379-B2 | Methods of inhibiting formation of alpha synuclein aggregates | SNCA, PARK7, PYGB | EPHX2 3967/4885 |
| US-20160256457-A1 | METHODS FOR TREATING OR PREVENTING ACUTE VASCULAR LEAK | BTK, ANTXR2, TBXA2R | EPHX2 1640/4885 |
| US-20090018092-A1 | Reducing Nephropathy with Inhibitors of Soluble Epoxide Hydrolase and Epoxyeicosanoids | EPHX1, EPHX2, NCEH1 | EPHX2 2/4885 |
| US-20230071934-A1 | NOVEL USES | SMPD1, PDE4A, PDE7A | EPHX2 534/4885 |
| US-20050026844-A1 | Inhibitors for the soluble epoxide hydrolase | EPHX1, EPHX2, NCEH1 | EPHX2 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.